NCT07012798View on ClinicalTrials.gov

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Hepatocellular Carcinoma (HCC)
Interventions
DRUG

Durvalumab

1120mg, iv, q3w

DRUG

Bevacizumab

15mg/kg, iv, q3w

DRUG

HAIC of FOLFOX

"HAIC (FOLFOX): oxaliplatin 100mg/m2, 4h, day 1 + leucovorin 300mg/m2, 2h, day~1 + fluorouracil 500mg/m2, 20min, day 1 + fluorouracil 1500mg/m2, 20h, q3w"

Trial Locations (1)

300308

Tianjin Cancer Hospital Airport Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER